Investigating the role of microbiota in small-intestine neuroendocrine tumors
Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors
This study is trying to see how the bacteria in the gut might affect the growth of small-intestine neuroendocrine tumors in people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Lyon, France) |
| Trial ID | NCT06624865 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore how the microenvironment, particularly the microbiota, influences the development of small-intestine neuroendocrine tumors, which are often found in the terminal ileum and lack identified driver mutations. Participants will undergo blood and stool sampling to gather data on their microbiota and tumor characteristics. The study seeks to enhance understanding of tumorigenesis in these specific tumors, potentially leading to new insights in treatment approaches.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have one or more small-intestine neuroendocrine tumors and are scheduled for surgery.
Not a fit: Patients with poorly differentiated neuroendocrine carcinoma, non-intestinal NETs, or mixed tumors, as well as pregnant or breastfeeding women, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the role of microbiota in tumor development, potentially leading to novel therapeutic strategies for patients with small-intestine neuroendocrine tumors.
How similar studies have performed: While the specific approach of examining microbiota in small-intestine neuroendocrine tumors may be novel, similar studies investigating the role of microbiota in other cancers have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with one or more small-intestine neuroendocrine tumor with indication of surgery * Patient with consent for the collection, storage and reuse of data associated with his/her disease * Age ≥ 18 years at the time of inclusion * Non-objection statement obtained for participation in the study Exclusion Criteria: * Patients with poorly differentiated neuroendocrine carcinoma or NET (neuroendocrine tumors) of non-intestinal origin or mixed tumors (MiNEN) * Pregnant, parturient or breast-feeding women * Minors * Persons deprived of liberty by judicial or administrative decision * Adults under legal protection (guardianship, curatorship)
Where this trial is running
Lyon, France
- Edouard Herriot University Hospital — Lyon, France, France (Recruiting)
Study contacts
- Study coordinator: Thomas WALTER, MD, PhD
- Email: thomas.walter@chu-lyon.fr
- Phone: 0472117398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.